Trials / Completed
CompletedNCT02363829
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
A Phase I Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients 18 years of age and older with clinical stages IIA, IIB, IIIA, IIIB, IVA cervical carcinoma limited to the pelvis will receive twice daily oral nelfinavir (NFV) and weekly IV cisplatin in combination as radiosensitizers with daily whole pelvic external beam and intracavitary radiation brachytherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nelfinavir | |
| BIOLOGICAL | Cisplatin |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2020-02-17
- Completion
- 2020-02-17
- First posted
- 2015-02-16
- Last updated
- 2020-04-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02363829. Inclusion in this directory is not an endorsement.